Cargando…
Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from being predominantly cytokine-based treatment to the use of targeted agents, which include sorafenib, sunitinib, bevacizumab (plus interferon alpha [IFN-α]), temsirolimus, everolimus, pazopanib, and most recently, axiti...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Urological Association
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332131/ https://www.ncbi.nlm.nih.gov/pubmed/22536463 http://dx.doi.org/10.4111/kju.2012.53.4.217 |